Inflammation in diabetic nephropathy.

Lim AK, Tesch GH. · 2012

Read Inflammation in diabetic nephropathy. by Lim AK, Tesch GH. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3432398.txt.

Introduction

Lim and Tesch reviewed the role of inflammation in diabetic nephropathy in 2012, the kidney damage that leads the world in causing end-stage kidney failure. Current care remains suboptimal, and the disease was not long seen as an inflammatory one. The review weighs evidence from human and animal diabetes and reports early attempts to treat the inflammation itself.

Immune cells, above all macrophages and T cells, enter the diabetic kidney early and help drive the damage. The authors cover the main cytokines, fat-derived signals, possible immune deposits, and two stress pathways inside kidney cells. Blocking inflammation in experiments has both taught the disease's mechanics and shown therapeutic promise. Genetic and drug approaches get a careful hearing.

Catalog record

CREATORLim AK, Tesch GH.
YEAR2012
COLLECTIONPAPERS
FORMATTXT
FILE SIZE63 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3432398

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Inflammation in Diabetic Nephropathy By Andy K. H. Lim, Gregory H. Tesch Published in: Mediators of Inflammation DOI: 10.1155/2012/146154 ABSTRACT Diabetic nephropathy is the leading cause of end-stage kidney disease worldwide but current treatments remain suboptimal. This review examines the evidence for inflammation in the development and progression of diabetic nephropathy in both experimental and human diabetes, and provides an update on recent novel experimental approaches targeting inflammation and the lessons we have learned from these approaches. We highlight the important role of inflammatory cells in the kidney, particularly infiltrating macrophages, T-lymphocytes and the subpopulation of regulatory T cells. The possible link between immune deposition and diabetic nephropathy is explored, along with the recently described immune complexes of anti-oxidized low-density lipoproteins. We also briefly discuss some of the major inflammatory cytokines involved in the pathogenesis of diabetic nephropathy, including the role of adipokines. Lastly, we present the latest data on the pathogenic role of the stress-activated protein kinases in diabetic nephropathy, from studies on the p38 mitogen activated protein kinase and the c-Jun amino terminal kinase cell signalling pathways. The genetic and pharmacological approaches which reduce inflammation in diabetic nephropathy have not only enhanced our understanding of the pathophysiology of the disease but shown promise as potential therapeutic strategies. 1. INTRODUCTION Diabetic nephropathy (DN) has not been traditionally considered an inflammatory disease. However, recent studies have shown that kidney inflammation is crucial in promoting the development and progression of DN. Inflammation may be a key factor which is activated by the metabolic, biochemical, and haemodynamic derangements known to exist in the diabetic kidney. In this paper, we discuss the evidence for inflammation in DN and the lessons we have learned from novel experimental anti-inflammatory therapies. The main areas covered include the role of immune and inflammatory cells, inflammatory cytokines, and stress-activated protein kinases. We also briefly review the controversy around the role of immune complexes and immune deposition in DN. 2. INFLAMMATORY CELLS In human DN, macrophages and T cells accumulate in the glomeruli and interstitium, even in the early stages of the disease. Recruitment of leukocytes involves three steps: (a) selectin-dependent leukocyte rolling on the endothelium, (b) chemokine-dependent integrin activation and leukocyte adhesion, and (c) transmigration of leukocytes across the endothelium [1]. Proinflammatory cytokines produced by leukocytes such as interleukin-1 (IL-1), tumour necrosis factor-α (TNF-α), and interferon-γ (INF-γ) can induce resident renal cells to produce a spectrum of chemokines. Elements of the diabetic milieu such as high glucose and advanced glycation end products (AGEs) are also potent stimulators of chemokine production. These chemokines include interleukin-8 (CXCL8), monocyte-chemoattractant protein-1 (MCP-1), INF-γ inducible protein (CXCL10), macrophage inflammatory protein-1α (MIP-1α/CCL3), and RANTES (CCL5). The elaborated chemokines then further direct the migration of additional leukocytes into the kidney and set up an inflammatory cycle. 2.1. Macrophages Macrophages are key inflammatory cells mediating kidney inflammation in experimental and human diabetes. Activated macrophages elaborate a host of proinflammatory, profibrotic, and antiangiogenic factors. These macrophage-derived products include but are not limited to TNF-α, IL-1, IL-6, reactive oxygen species (ROS), plasminogen activator inhibitor-1 (PAI-1), matrix metalloproteinases, transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), angiotensin II, and endothelin [1]. In experimental diabetic mice, macrophage accumulation and activation are associated with prolonged hyperglycaemia, glomerular immune complex deposition, increased chemokine production, and progressive fibrosis [2, 3]. In human type 2 diabetes, kidney macrophage accumulation is associated with the degree of glomerular sclerosis [4]. In another human study, interstitial macrophage accumulation correlated strongly with serum creatinine, proteinuria, and interstitial fibrosis at the time of biopsy, and inversely with the renal function decline (slope of 1/serum creatinine) over the following 5 years [5]. These human data support animal studies in suggesting a pathological role for macrophages in DN. Strategies impairing kidney leukocyte recruitment have added evidence that macrophages mediate diabetic kidney injury. Increased kidney expression of intercellular adhesion molecule-1 (ICAM-1) has been noted in models of type 1 and type 2 diabetes. ICAM-1 serves as a ligand for LFA-1 on monocytes, facilitating leukocyte adhesion and transmigration. Diabetic ICAM-1 knockout mice showed significant reduction in albuminuria, glomerular, and tubulointerstitial injury, in association with a reduction in macrophage accumulation in the kidney [6]. However, ICAM-1 deficiency affects macrophages and lymphocytes, so these studies do not distinguish the roles of macrophages and lymphocytes. Like ICAM-1, MCP-1 is also significantly increased in DN and expression levels correlate with the number of infiltrating interstitial macrophages. Studies suggest that renal MCP-1 is involved in the direction of macrophage migration into the diabetic kidney, while proteinuria itself may contribute to this upregulation of MCP-1 [7]. Blockade of the MCP-1 receptor (CCR-2) with a selective antagonist ameliorated diabetic glomerular sclerosis [8]. Similarly, diabetic db/db mice and streptozotocin-(STZ-) induced diabetic mice which are deficient in the gene encoding MCP-1 (Ccl2) are protected from renal injury [9, 10]. To further test the pathogenic role of macrophages, we used c-fms blockade to selectively target macrophages during the progression of experimental DN [11]. c-fms is the receptor for colony stimulating factor-1 (CSF-1), the major cytokine promoting macrophage accumulation, activation, and survival. We administered a neutralizing anti-c-fms monoclonal antibody to diabetic db/db mice with established albuminuria. This inhibition suppressed inflammation in the diabetic kidney, as evidenced by the reduction in macrophage accumulation, activation, and proliferation. Along with the effects on macrophages, there was a reduction in MCP-1, TNF-α, and c-Jun amino terminal kinase (JNK) activation. This resulted in a reduction in glomerular hyperfiltration, tubulointerstitial injury, and fibrosis. The evidence so far indicates that infiltrating macrophages are associated with chronic, low-grade inflammation. Macrophages can interact with resident renal cells to generate a proinflammatory microenvironment that amplifies tissue injury and promotes scarring. As we have shown, macrophage-mediated injury is amenable to novel secondary prevention strategies. 2.2. Lymphocytes A T cell infiltrate into diabetic kidneys has long been appreciated but not well studied. The role of T cells in kidney disease is better characterized in crescentic glomerulonephritis, such as antiglomerular basement membrane (GBM) disease [12]. Kidney infiltration by CD4+ and CD8+ T cells has been noted in diabetic db/db mice and diabetic NOD mice [2, 13]. In the latter study, glomerular B-cells were also found to be increased. A kidney T cell influx is common among young patients with early type 1 diabetes, especially those with a shorter duration of diabetes, and correlates with renal function and albuminuria [14]. This T cell accumulation has been noted in the juxtaglomerular apparatus of these patients but the functional role of T cells in this compartment is unclear. It has been reported that the homing of Th1 cells in glomeruli is P-selectin and ICAM-1 dependent and associated with increased levels of IFN-γ and macrophage migration inhibitory factor (MIF) in crescentic Th1-mediated glomerulonephritis [15]. Although the mechanisms of Th1 cell migration in models of DN have not been reported yet, levels of ICAM-1 and P-selectin are increased within the diabetic kidney. As T cells constitutively express LFA-1, and ICAM-1 expression is found on renal endothelial, epithelial, and mesangial cells, it is likely that this interaction plays a significant role in T cell migration into the kidney. This is supported by a study showing that glomerular accumulation of CD4+ T cells was decreased in ICAM-1-deficient db/db mice [6]. Human and rat T

Read the complete text